Technology | 2018.10.18
Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About CRISPR-Cas9 Gene-Editing Therapies
Four months ago, alarms were set off by two reports showing that CRISPR-Cas9 gene editing of non-transformed human cells occurred with a high frequency of carcinogenic mutations in the p53 cancer gene. Though some experts worried that there would be no easy solution to this problem, published in today’s October issue of The CRISPR Journal, stem cell biotechnology company Asymmetrex suggests a simple stemgene solution based on an often overlooked function of the p53 gene in adult tissue stem cell kinetics regulation.
(PRWeb October 18, 2018)
Read the full story at https://www.prweb.com/releases/asymmetrex_suggests_a_stemgene_relief_from_recent_cancer_woes_about_crispr_cas9_gene_editing_therapies/prweb15848432.htm
For more information, please visit
https://www.prweb.com/releases/asymmetre[...]ng_therapies/prweb15848432.htm
